A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor

Journal of the American Academy of Dermatology

Volumn 61, Issue 6, 2009, Pages 971-976

  Faergemann, Jan ^a   Todd, Gail ^b   Pather, Sandrakantha ^c   Vawda, Zubar F A ^d   Gillies, John D ^e   Walford, Ted ^e   Barranco, Charles ^f   Quiring, John N ^g   Briones, Manuel ^g  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d P3 Research Ltd ^*

^e Barrier Therapeutics   (United States)

^f QST Consultations Ltd   (United States)

^g QST Consultations Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; PLACEBO; PRAMICONAZOLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TINEA VERSICOLOR; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MALE; TINEA VERSICOLOR; TRIAZOLES;

EID: 71549171724     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.08.033     Document Type: Article

References (10)

1. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 1 (2000) 75-80
2. Odds F., Ausma J., Van Gerven F., Woestenborghs F., Meerpoel L., Heeres J., et al. In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob Agents Chemother 48 (2004) 388-391
3. Meerpoel L., Backx L.J., Van der Veken L.J., Heeres J., Corens D., De Groot A., et al. Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. J Med Chem 48 (2005) 2184-2193
4. Vanden Bossche H., Ausma J., Bohets H., Vermuyten K., Willemsens G., Marichal P., et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother 48 (2004) 3272-3278
5. Piérard-Franchimont C., Ausma J., Wouters L., Vroome V., Vandeplassche L., Borgers M., et al. Activity of the triazole antifungal R126638 as assessed by corneofungimetry. Skin Pharmacol Physiol 19 (2006) 50-56
6. Faergemann J., Ausma J., and Borgers M. The in vitro activity of R126638 and ketoconazole against Malassezia species. Acta Derm Venereol 86 (2006) 312-315
7. Faergemann J., Ausma J., Vandeplassche L., and Borgers M. The efficacy of oral treatment with pramiconazole in pityriasis versicolor: a phase IIa trial. Br J Dermatol 156 (2007) 1385-1388
8. Mesens J.L., Putteman P., and Verheyen P. Pharmaceutical applications of 2-hydroxypropyl-ß-cyclodextrin. In: Duchene D. (Ed). New trends in cyclodextrins and derivatives (1991), Editions de Sante, Paris 369-407
9. Stevens D.A. Itraconazole in cyclodextrin solution. Pharmacotherapy 19 (1999) 603-611
10. Walsh T.J., Viviani M.A., Arathoon E., Chiou C., Ghannoum M., Groll A.H., et al. New targets and delivery systems for antifungal therapy. Med Mycol 38 Suppl (2000) 335-347